Rare Endocrine Exchange: Why This Conversation Matters @checkrare
Rare Endocrine Exchange: Why This Conversation Matters  @checkrare
Uploaded August 2026 | Updated November 2026, 5 days ago
Rare endocrine disorders can be difficult to recognize, challenging to diagnose, and even harder for patients to navigate. For many patients, the journey to an accurate diagnosis can take years.

Rare Endocrine Exchange, a new podcast from CheckRare, aims to change that.
Hosted by clinical endocrinologist Margarita Ochoa-Maya, MD, the series brings together physicians, researchers, patients, advocates, and other leaders across the rare endocrine community to explore the science, challenges, and real-world experiences behind these disorders.

In this inaugural episode, Dr. Ochoa-Maya introduces the Rare Endocrine Exchange and discusses why greater awareness and collaboration are needed across rare endocrine diseases. Future episodes will explore some of the most important issues facing the community, including:

• Why are rare endocrine disorders diagnosed so slowly?
• Can AI help (or hurt) rare endocrine care?
• What do new guidelines mean for patients with rare endocrine diseases?
• The latest research and clinical advances
• Patient and caregiver experiences
• Advocacy and access to care
• Emerging treatments and clinical trialsThe goal is simple: to create a place where the rare endocrine community can learn from one another.

Whether the conversation is with a leading researcher, a practicing clinician, a patient, or an advocate working to change the system, Dr. Ochoa-Maya will explore the issues that matter most to the people living with and caring for rare endocrine disorders.

This is the Rare Endocrine Exchange.
Rare Endocrine Exchange: Why This Conversation MattersBeyond AChR: Recognizing and Treating MuSK Ab+, LRP4, Ab+ and Triple Seronegative Myasthenia GravisSafety and Efficacy of Subcutaneous Efgartigimod PH20 in Ocular Myasthenia GravisNew Huntingtons Disease Gene Therapy Application | The CheckRare Brief Ep 6New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | Ep 5FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic SyndromeMyasthenia Gravis Foundation of America (MGFA) Scientific SessionAlexander Disease and the Approval of Zanvastro (Zilganersen)Topline Results From the SANRECO Trial Testing Divesiran in Polycythemia VeraNew Treatment Option for Recurrent Respiratory Papillomatosis3D Printed Treatment Options | The CheckRare BriefResults From the PROGRESS Study of Zilurgisertib in Patients With FOP
CheckRare |

Rare Endocrine Exchange: Why This Conversation Matters

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER